Vitiligo is a common acquired skin disease of unknown
etiology that results in depigmentation. It is clinically
characterized by the development of white macules
due to selective loss of melanocytes. Lesions typically develop
in areas of friction, reflecting koebnerization. Depigmentation,
while asymptomatic, may lead to diminished quality of life and
severe psychological stress due to cosmetic concerns.1 There
is increasing evidence that vitiligo is an autoimmune disorder
that shows a genetic predisposition in about 18% of cases.2 It
occurs in approximately 1% of the U.S. population with equal
frequencies between men and women; half of all patients manifest
the disease before 20 years of age.
Topical Steroids Calcineurin Inhibitors (tacrolimus = Protopic pimecrolimus =
Elidel®) Vitamin D Analogues Systemic Steroids VitaminsCalcineurin Inhibitors (tacrolimus = Protopic pimecrolimus =
Narrowband UVB (NB UVB) PUVA Laser Therapy Camouflage Depigmentation TherapyPUVA
Punch Minigrafting Suction Blister Grafting Thin Dermoepidermal Grafts (Split-thickness Skin Grafts) Non Cultured Epidermal Suspensions Cultured Epidermis and MelanocytesSuction Blister Grafting
- Alikhan Ali, Felsten Lesley M, et. al. Vitiligo: A Comprehensive Overview,
Part I. J Am Acad Dermatol 2011;65:473-91.
- Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exp Dermatol 2005;30:344–5.